Salem, Heba F. Moubarak, Ghada Abdelsabour Ali, Adel A. Salama, Abeer A.A. Salama, Alaa H.
Published in
Journal of Pharmaceutical Sciences
Budesonide (BUD), a glucocorticoids drug, inhibits all steps in the inflammatory response. It can reduce and treat inflammation and other symptoms associated with acute lung injury such as COVID-19. Loading BUD into bilosomes could boost its therapeutic activity, and lessen its frequent administration and side effects. Different bilosomal formulati...
Sahin, Gokben Akbal-Dagistan, Ozlem Culha, Meltem Erturk, Aybige Basarir, Nur Sena Sancar, Serap Yildiz-Pekoz, Ayca
Published in
Journal of pharmaceutical sciences
Coronavirus Disease 2019 (COVID-19) pandemic has been on the agenda of humanity for more than 2 years. In the meantime, the pandemic has caused economic shutdowns, halt of daily lives and global mobility, overcrowding of the healthcare systems, panic, and worse, more than 6 million deaths. Today, there is still no specific therapy for COVID-19. Res...
Lewis, Lavinia M Badkar, Advait V Cirelli, David Combs, Rodney Lerch, Thomas F
Published in
Journal of Pharmaceutical Sciences
At the outset of the coronavirus disease 2019 (COVID-19) pandemic, it was clear that a vaccine would be crucial for global health efforts. The Pfizer and BioNTech teams came together in a race against the virus, working to design, test, manufacture, and distribute a safe and efficacious vaccine in record time for people around the world. Here, we p...
Peele, K Abraham Kumar, Vikas Parate, Shraddha Srirama, Krupanidhi Lee, Keun Woo Venkateswarulu, T C
Published in
Journal of pharmaceutical sciences
The novel coronavirus (SARS-CoV-2) outbreak has started taking away the millions of lives worldwide. Identification of known and approved drugs against novel coronavirus disease (COVID-19) seems to be an urgent need for the repurposing of the existing drugs. So, here we examined a safe strategy of using approved drugs of SuperDRUG2 database against...
Bhujbal, Sonal V Pathak, Vaibhav Zemlyanov, Dmitry Y Taylor, Lynne S Zhou, Qi Tony
Published in
Journal of pharmaceutical sciences
This study aims to develop amorphous solid dispersion (ASD) of lumefantrine with a cost-effective approach of spray anti-solvent precipitation. Four acidic polymers, hydroxypropylmethylcellulose phthalate (HPMCP), hydroxypropylmethylcellulose acetate succinate (HPMCAS), poly(methacrylic acid-ethyl acrylate) (EL100) and cellulose acetate phthalate (...
Perazzolo, Simone Zhu, Linxi Lin, Weixian Nguyen, Alexander Ho, Rodney J Y
Published in
Journal of pharmaceutical sciences
Over 50 million people have been infected with the SARS-CoV-2 virus, while around 1 million have died due to COVID-19 disease progression. COVID-19 presents flu-like symptoms that can escalate, in about 7-10 days from onset, into a cytokine storm causing respiratory failure and death. Although social distancing reduces transmissibility, COVID-19 va...
Sawant, Nishant Kaur, Kawaljit Holland, David A Hickey, John M Agarwal, Sanjeev Brady, Joseph R Dalvie, Neil C Tracey, Mary Kate Velez-Suberbie, M Lourdes Morris, Stephen A
...
Published in
Journal of pharmaceutical sciences
A two-step developability assessment workflow is described to screen variants of recombinant protein antigens under various formulation conditions to rapidly identify stable, aluminum-adjuvanted, multi-dose vaccine candidates. For proof-of-concept, a series of sequence variants of the recombinant non-replicating rotavirus (NRRV) P[8] protein antige...
Kaur, Kawaljit Xiong, Jian Sawant, Nishant Agarwal, Sanjeev Hickey, John M. Holland, David A. Mukhopadhyay, Tarit K. Brady, Joseph R. Dalvie, Neil C. Tracey, Mary Kate
...
Published in
Journal of Pharmaceutical Sciences
In a companion paper, a two-step developability assessment is presented to rapidly evaluate low-cost formulations (multi-dose, aluminum-adjuvanted) for new subunit vaccine candidates. As a case study, a non-replicating rotavirus (NRRV) recombinant protein antigen P[4] was found to be destabilized by the vaccine preservative thimerosal, and this eff...
Kumar, Prashant Pullagurla, Swathi R. Patel, Ashaben Shukla, Ravi S. Bird, Christopher Kumru, Ozan S. Hamidi, Ahd Hoeksema, Femke Yallop, Christopher Bines, Julie E.
...
Published in
Journal of Pharmaceutical Sciences
• Formulation development for oral delivery of a live, rotavirus vaccine candidate (RV3-BB) is described. • RV3-BB virus stability during in vivo oral delivery was mimicked with two different in vitro gastric digestion models. • Pre-neutralization with infant formula (Enfamil®) or antacid (Mylanta®) conferred partial to full protection of RV3-BB. •...
Darriba, M. Laura Cerutti, María L. Bruno, Laura Cassataro, Juliana Pasquevich, Karina A.
Published in
Journal of Pharmaceutical Sciences
Unlipidated outer membrane protein 19 (U-Omp19) is a novel mucosal adjuvant in preclinical development to be used in vaccine formulations. U-Omp19 holds two main properties, it is capable of inhibiting gastrointestinal and lysosomal peptidases, increasing the amount of co-administered antigen that reaches the immune inductive sites and its half-lif...
